NYSE · Price History

Teva Pharmaceutical Industries Limited (TEVA) Stock Price History & Returns

$42.62 NYSE: TEVA Market Cap $49.73B

Price history through Nov 17, 2026 · Source: Yahoo Finance (adjusted closes) (methodology)

How Teva Pharmaceutical Industries Limited (TEVA) has performed, year by year and over each trailing period. Price history only — total return to a shareholder would also include dividends.

The share price of $42.62 sits 91% of the way up a 52-week range of $24.01 to $44.50; 4.2% below the 52-week high; above its 50-day moving average of $39.76; above its 200-day average of $34.94; a beta of 0.84 means it has historically moved less than the market.

Total return

Price change over each trailing period, not annualised.

PeriodReturn
3 months+11.9%
6 months+22.7%
1 year+70.5%
3 years+363.2%
5 years+366.3%

Year by year

27 of 42 years closed higher than the year before. Closes are the last observation in each calendar year.

YearCloseChange
2026$42.62+25.1%
2025$34.08+92.2%
2024$17.73+46.5%
2023$12.10+14.8%
2022$10.54+25.0%
2021$8.43-28.4%
2020$11.78+13.3%
2019$10.40-47.6%
2018$19.85-2.7%
2017$20.41-36.9%
2016$32.34-44.1%
2015$57.82+10.6%
2014$52.29+30.8%
2013$39.97+21.4%
2012$32.93-13.7%
2011$38.15-15.8%
2010$45.29-2.3%
2009$46.35+38.6%
2008$33.45-9.0%
2007$36.74+32.4%
2006$27.74-17.0%
2005$33.41+49.6%
2004$22.33-7.5%
2003$24.15+64.0%
2002$14.73+24.7%
2001$11.81+15.6%
2000$10.22+65.1%
1999$6.19+51.3%
1998$4.09-4.7%
1997$4.29-15.7%
1996$5.09+22.7%
1995$4.15+75.1%
1994$2.37-18.6%
1993$2.91+36.6%
1992$2.13+113.0%
1991$1.00+61.3%
1990$0.62+19.2%
1989$0.52+85.7%
1988$0.28+33.3%
1987$0.21-40.0%
1986$0.35+150.0%
1985$0.14+75.0%

Monthly closing prices

The last 36 months, newest first. 19 of 36 months closed higher than the month before. Each figure is the last close in that month.

MonthCloseChange
November 2026$42.62+1.3%
August 2026$42.09+20.2%
May 2026$35.01-0.2%
February 2026$35.07+2.9%
November 2025$34.08+66.4%
August 2025$20.48+32.6%
May 2025$15.45-0.4%
February 2025$15.51-12.5%
November 2024$17.73-3.9%
August 2024$18.44+5.8%
May 2024$17.43+24.1%
February 2024$14.05+16.1%
November 2023$12.10+41.0%
August 2023$8.58+2.1%
May 2023$8.40-3.8%
February 2023$8.73-17.2%
November 2022$10.54+18.2%
August 2022$8.92-4.9%
May 2022$9.38+7.7%
February 2022$8.71+3.3%
November 2021$8.43-3.5%
August 2021$8.74-9.4%
May 2021$9.65-9.8%
February 2021$10.70-9.2%
November 2020$11.78+35.1%
August 2020$8.72-24.4%
May 2020$11.54+7.4%
February 2020$10.74+3.3%
November 2019$10.40+27.6%
August 2019$8.15+2.8%
May 2019$7.93-47.9%
February 2019$15.22-23.3%
November 2018$19.85-0.7%
August 2018$19.98-16.5%
May 2018$23.94+33.1%
February 2018$17.98-11.9%

Teva Pharmaceutical Industries Limited (TEVA) price history — frequently asked questions

How has Teva Pharmaceutical Industries Limited performed over the last year?

Teva Pharmaceutical Industries Limited (TEVA) has risen 70.5% over the last twelve months, measured on price alone.

What is Teva Pharmaceutical Industries Limited's five-year return?

Over five years the TEVA share price has gained 366.3%, excluding dividends.

What is Teva Pharmaceutical Industries Limited's 52-week range?

Over the last year Teva Pharmaceutical Industries Limited (TEVA) has traded between $24.01 and $44.50.

Price returns of other Drug Manufacturers - Specialty & Generic stocks

ZTS 1-year -28.0%VTRS 1-year +98.8%ELAN 1-year +20.7%RDY 1-year +7.0%ALKS 1-year +51.7%AMRX 1-year +85.6%LNTH 1-year +91.3%SUPN 1-year +28.4%BHC 1-year +26.1%RGC 1-year -62.0%All Drug Manufacturers - Specialty & Generic stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNYSE High ROE StocksAll stock screens

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.